AU2009325117C1 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto - Google Patents

Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto Download PDF

Info

Publication number
AU2009325117C1
AU2009325117C1 AU2009325117A AU2009325117A AU2009325117C1 AU 2009325117 C1 AU2009325117 C1 AU 2009325117C1 AU 2009325117 A AU2009325117 A AU 2009325117A AU 2009325117 A AU2009325117 A AU 2009325117A AU 2009325117 C1 AU2009325117 C1 AU 2009325117C1
Authority
AU
Australia
Prior art keywords
methyl
methoxy
pyrazol
cyclohexyl
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009325117A
Other languages
English (en)
Other versions
AU2009325117B2 (en
AU2009325117A1 (en
Inventor
Jason B. Ibarra
Young-Jun Shin
Thuy-Anh Tran
Brett Ullman
Xi Zeng
Ning Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of AU2009325117A1 publication Critical patent/AU2009325117A1/en
Publication of AU2009325117B2 publication Critical patent/AU2009325117B2/en
Application granted granted Critical
Publication of AU2009325117C1 publication Critical patent/AU2009325117C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009325117A 2008-11-26 2009-11-24 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto Active AU2009325117C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20039308P 2008-11-26 2008-11-26
US61/200,393 2008-11-26
PCT/US2009/006251 WO2010068242A1 (en) 2008-11-26 2009-11-24 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Publications (3)

Publication Number Publication Date
AU2009325117A1 AU2009325117A1 (en) 2010-06-17
AU2009325117B2 AU2009325117B2 (en) 2014-07-10
AU2009325117C1 true AU2009325117C1 (en) 2014-12-18

Family

ID=41718771

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009325117A Active AU2009325117C1 (en) 2008-11-26 2009-11-24 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

Country Status (15)

Country Link
US (6) US20110224262A1 (enExample)
EP (2) EP2367797A1 (enExample)
JP (1) JP5603343B2 (enExample)
KR (1) KR101707247B1 (enExample)
CN (1) CN102292321B (enExample)
AU (1) AU2009325117C1 (enExample)
BR (1) BRPI0921369B8 (enExample)
CA (1) CA2744124C (enExample)
EA (1) EA022799B1 (enExample)
IL (1) IL212966A (enExample)
MX (1) MX2011005577A (enExample)
NZ (1) NZ593002A (enExample)
SG (1) SG171413A1 (enExample)
WO (1) WO2010068242A1 (enExample)
ZA (1) ZA201103813B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280696B9 (en) * 2008-03-18 2015-12-09 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
EP2367797A1 (en) 2008-11-26 2011-09-28 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US8940891B2 (en) * 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
CN103842066B (zh) 2011-09-30 2016-08-24 日本化成株式会社 聚合性无机颗粒分散剂、含有该聚合性无机颗粒分散剂的无机有机复合颗粒以及无机有机树脂复合材料
US9314026B2 (en) 2011-10-06 2016-04-19 Bayer Intellectual Property Gmbh Heterocyclylpyri(mi)dinylpyrazole
PL2763987T3 (pl) 2011-10-06 2019-01-31 Bayer Cropscience Ag Heterocyklilopiry(mi)dynylopirazole jako środki grzybobójcze
NZ731751A (en) 2014-10-23 2023-07-28 Arena Pharm Inc Method of treating conditions related to the pgi2 receptor
JP2019533713A (ja) 2016-11-10 2019-11-21 アレーナ ファーマシューティカルズ,インク. ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
CN110582271B (zh) * 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
WO2019154363A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 前列环素受体受体激动剂
WO2019222764A1 (en) 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
AU2023222747A1 (en) 2022-02-15 2024-08-22 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849919A (en) * 1991-12-27 1998-12-15 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity
US20060258728A1 (en) * 2001-08-09 2006-11-16 Kousuke Tani Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021451A (en) 1911-04-22 1912-03-26 James F Craven Receptacle for containing and discharging semisolid and pasty substances.
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
JP3160438B2 (ja) 1993-09-29 2001-04-25 株式会社東芝 交通流予測装置
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) * 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) * 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
MXPA05008450A (es) * 2003-02-10 2005-10-18 Vertex Pharma Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人21あおもり産業総合支援センター U字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
CA2576971A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
TW200621261A (en) * 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Dic株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
BRPI0713096A2 (pt) 2006-05-09 2012-10-16 Hemaquest Pharmaceuticals Inc métodos para tratar distúrbios sangüìneos
EP2280696B9 (en) 2008-03-18 2015-12-09 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
EP2367797A1 (en) 2008-11-26 2011-09-28 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US8940891B2 (en) * 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
US20120225937A1 (en) 2009-09-23 2012-09-06 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pg12 receptor agonists
WO2019032626A1 (en) 2017-08-07 2019-02-14 Arena Pharmaceuticals, Inc. Methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849919A (en) * 1991-12-27 1998-12-15 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity
US20060258728A1 (en) * 2001-08-09 2006-11-16 Kousuke Tani Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient

Also Published As

Publication number Publication date
US20110224262A1 (en) 2011-09-15
AU2009325117B2 (en) 2014-07-10
KR20110095914A (ko) 2011-08-25
JP2012509936A (ja) 2012-04-26
EP3342767B1 (en) 2021-04-14
CA2744124A1 (en) 2010-06-17
US20140171469A1 (en) 2014-06-19
SG171413A1 (en) 2011-07-28
CN102292321A (zh) 2011-12-21
WO2010068242A1 (en) 2010-06-17
US20150191455A1 (en) 2015-07-09
US10214518B2 (en) 2019-02-26
NZ593002A (en) 2013-08-30
CN102292321B (zh) 2015-08-12
US10689372B2 (en) 2020-06-23
US20180030039A1 (en) 2018-02-01
EP2367797A1 (en) 2011-09-28
US9012478B2 (en) 2015-04-21
US9663500B2 (en) 2017-05-30
ZA201103813B (en) 2012-10-31
BRPI0921369B8 (pt) 2021-05-25
BRPI0921369A2 (pt) 2015-12-29
BRPI0921369B1 (pt) 2020-09-29
CA2744124C (en) 2018-05-01
US11098034B2 (en) 2021-08-24
EA201100846A1 (ru) 2012-01-30
EA022799B1 (ru) 2016-03-31
JP5603343B2 (ja) 2014-10-08
HK1257652A1 (en) 2019-10-25
IL212966A0 (en) 2011-07-31
US20200392123A1 (en) 2020-12-17
IL212966A (en) 2015-03-31
US20190270731A1 (en) 2019-09-05
KR101707247B1 (ko) 2017-02-15
MX2011005577A (es) 2011-08-03
EP3342767A1 (en) 2018-07-04
AU2009325117A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
AU2009325117C1 (en) Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
US10793529B2 (en) Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators
KR101670089B1 (ko) 프로스타시클린 (pgi2) 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
HK1257652B (en) Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 AUG 2014

FGA Letters patent sealed or granted (standard patent)